Adipose tissue dysfunction and the liver: reframing MASH as the hepatic expression of systemic metabolic dysfunction
- 1Department of Internal Medicine, National Relevance and High Specialization Hospital Trust ARNAS Civico, Di Cristina
- 2Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties [PROMISE], University of Palermo
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is conventionally investigated and treated as a primary disease of the liver. In type 2 diabetes, however, the hepatic lesion is best understood as the visible endpoint of a systemic disorder of adipose tissue. This review develops the mechanistic case for that reading. We trace a single causal narrative: from adipose tissue dysfunction (ATD), the immuno-inflammatory and endocrine failure of dysfunctional adipose tissue, through a reconfigured adipokine secretome and adipose inflammation, to selective insulin resistance and a systemic loss of metabolic flexibility, and thence to the lipid and inflammatory burden that the liver, by virtue of its portal anatomy and metabolic role, is uniquely exposed to. Within this framework, hepatic steatosis is the expected consequence of failed peripheral lipid buffering, and steatohepatitis the readout of lipotoxic, immunometabolic injury rather than an autonomous hepatic process. We argue that MASH is more faithfully interpreted as the hepatic expression of systemic adipose tissue dysfunction than as a primary liver disease, and that this reframing relocates both mechanistic enquiry and the most rational point of therapeutic intervention upstream, to adipose biology and fuel handling. We propose adipose dysfunction as a major, phenotype-dependent upstream driver of T2D-associated MASH that interacts bidirectionally with hepatic, genetic and gut-derived mechanisms, rather than as its sole, universal or unidirectional cause. The argument is advanced as a biologically coherent framework intended to inform how the disorder is conceived and studied.
Related
- Obesity, Metabolic Modulation, and Arrhythmias: From Adipose Tissue Dysfunction to a Modifiable Arrhythmogenic Substrate
- MRI-based proton density fat fraction combined with adipose tissue for identifying metabolic dysfunction-associated steatohepatitis
- Adipose Tissue Pericellular Fibrosis, Weight Loss and Features of Metabolic Dysfunction-Associated Steatotic Liver Disease after Bariatric Surgery
- Long-term effect of sweeteners and sweetness enhancers on gene expression markers of adipose tissue function, adipocyte morphology, and metabolic health: a SWEET substudy
- Circulating MicroRNAs Reflect Systemic Inflammation and Metabolic Dysfunction in Oesophageal Squamous Cell Carcinoma-Associated Cachexia.
BibTeX
@article{corrao2026adipose,
title = {{Adipose tissue dysfunction and the liver: reframing MASH as the hepatic expression of systemic metabolic dysfunction}},
author = {Salvatore Corrao and Christiano Argano},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1920879},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1920879/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Adipose tissue dysfunction and the liver: reframing MASH as the hepatic expression of systemic metabolic dysfunction
AU - Salvatore Corrao
AU - Christiano Argano
PY - 2026
DA - 2026/10/22
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1920879
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1920879/full
AB - Metabolic dysfunction-associated steatohepatitis (MASH) is conventionally investigated and treated as a primary disease of the liver. In type 2 diabetes, however, the hepatic lesion is best understood as the visible endpoint of a systemic disorder of adipose tissue. This review develops the mechanistic case for that reading. We trace a single causal narrative: from adipose tissue dysfunction (ATD), the immuno-inflammatory and endocrine failure of dysfunctional adipose tissue, through a reconfigured adipokine secretome and adipose inflammation, to selective insulin resistance and a systemic loss of metabolic flexibility, and thence to the lipid and inflammatory burden that the liver, by virtue of its portal anatomy and metabolic role, is uniquely exposed to. Within this framework, hepatic steatosis is the expected consequence of failed peripheral lipid buffering, and steatohepatitis the readout of lipotoxic, immunometabolic injury rather than an autonomous hepatic process. We argue that MASH is more faithfully interpreted as the hepatic expression of systemic adipose tissue dysfunction than as a primary liver disease, and that this reframing relocates both mechanistic enquiry and the most rational point of therapeutic intervention upstream, to adipose biology and fuel handling. We propose adipose dysfunction as a major, phenotype-dependent upstream driver of T2D-associated MASH that interacts bidirectionally with hepatic, genetic and gut-derived mechanisms, rather than as its sole, universal or unidirectional cause. The argument is advanced as a biologically coherent framework intended to inform how the disorder is conceived and studied.
SN - 1664-2392
ER -